| 13.79 -0.701 (-4.84%) | 06-17 13:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.25 |
1-year : | 18.68 |
| Resists | First : | 14.76 |
Second : | 16 |
| Pivot price | 14.03 |
|||
| Supports | First : | 12.77 |
Second : | 10.63 |
| MAs | MA(5) : | 13.94 |
MA(20) : | 14.02 |
| MA(100) : | 16.58 |
MA(250) : | 14.75  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 32.6 |
D(3) : | 34.6 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 42.11 | Low : | 3.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APLM ] has closed below the lower bollinger band by 8.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ APLM ] is to continue within current trading range. It is unclear right now based on current values. 68.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.5 - 14.61 | 14.61 - 14.69 |
| Low: | 13.81 - 13.92 | 13.92 - 14 |
| Close: | 14.35 - 14.52 | 14.52 - 14.65 |
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Tue, 16 Jun 2026
Apollomics (APLM) CEO Hung-Wen Chen gains 5,000 shares as RSUs vest - Stock Titan
Tue, 16 Jun 2026
Apollomics (APLM) director acquires 500 shares through RSU vesting - Stock Titan
Tue, 16 Jun 2026
Apollomics (APLM) director vests 500 RSUs into Class A shares - Stock Titan
Tue, 16 Jun 2026
[Form 4] Apollomics Inc. Insider Trading Activity - Stock Titan
Tue, 16 Jun 2026
Director at Apollomics (APLM) gains 500 shares from vested RSUs - Stock Titan
Mon, 27 Apr 2026
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.26e+006 (%) |
| Held by Institutions | 53.3 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.09e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -123.8 % |
| Operating Margin | 431.8 % |
| Return on Assets (ttm) | -57.7 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 8.84e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 199.58 |
| EBITDA (p.s.) | 5.77778e+006 |
| Qtrly Earnings Growth | -7.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.06 |
| Price to Cash Flow | -13.75 |
| Dividend | 0 |
| Forward Dividend | 1590 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|